Unlocking Intracellular Delivery of Large Molecules with Sapreme’s SPT001 platform

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

>> website Sapreme Technologies

Ruben Postel | Chief Scientific Officer and Founder of Sapreme

Ruben is the Chief Scientific Officer and Founder of Sapreme. At Sapreme, he steers the scientific developments and innovation of the company to enable the challenge of endosomal entrapment of payloads, paving the way for next-generation therapeutic development. Ruben earned his Ph.D. in Developmental Biology and Genetics from the Hubrecht Institute and worked as a postdoctoral fellow at The Netherlands Cancer Institute (NKI) in the department of Cell Biology. Before founding Sapreme Technologies, he gained experience in the ecosystem of biotech startups working on the development of tumor angiogenesis inhibitors.